FAQ on Soligenix Inc.'s Pioneering Treatment for Oral Mucositis

What is severe oral mucositis (SOM) and why is it a concern?

Severe oral mucositis (SOM) is a debilitating side effect of cancer therapy that often requires hospitalization, opioid pain management, and feeding tube placement, significantly lowering patients’ quality of life.

What is SGX942 and how does it work?

SGX942 is a novel therapeutic developed by Soligenix aimed at reducing tissue inflammation, promoting healing, and supporting immune response in patients with oral mucositis.

What phase is SGX942 currently in for clinical trials?

Soligenix is analyzing combined phase 2 and 3 datasets to design a second phase 3 study for SGX942.

Who is most affected by oral mucositis?

Oral mucositis is exceptionally common among patients receiving head and neck cancer treatments, with nearly all experiencing some degree of the condition.

Are there any FDA-approved treatments for oral mucositis?

Currently, there are no FDA-approved treatments for oral mucositis, highlighting the urgent need for effective interventions like SGX942.

Where can I find more information about Soligenix and SGX942?

More information about Soligenix and SGX942 can be found in the company’s newsroom at https://ibn.fm/SNGX and on BioMedWire’s website https://www.biomedwire.com/.

What makes SGX942 a promising treatment for oral mucositis?

SGX942 has shown promising phase 3 data, demonstrating substantial improvements in the duration and severity of mucositis in head and neck cancer patients.

How does oral mucositis affect cancer patients?

Oral mucositis causes painful ulcers, inflammation, and impaired oral function, significantly impacting the quality of life for cancer patients undergoing treatment.